MVA Investors, LLC
CIK: 0001468223
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.
Transaction History
| TNGX | ▼ Sell | Open Market | 95,000 | $825K | 7/2/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 110,731 | $982K | 7/1/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 29,000 | $249K | 6/28/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 77,000 | $530K | 6/7/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 63,000 | $456K | 6/6/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 60,000 | $457K | 5/3/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 75,000 | $567K | 5/2/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 75,000 | $557K | 5/1/2024 | View on chart |
| TYRA | ▼ Sell | Open Market | 65,568 | $879K | 2/10/2023 | View on chart |
| TYRA | ▼ Sell | Open Market | 200,000 | $2.6M | 2/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.